Financial Summary


Therapix Biosciences Ltd.

Therapix Biosciences Ltd. (TRPX)

0.317 €
-0.313 (-49.68%)
Buy
A+
Market Info
Financial Info
Financial Modelling
Symbol TRPX
Price 0.317$
Beta 0.18
Volume Avrg. 1.58M
Market Cap 0.00B
Shares (2018) -
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE 4607.03% Strong Buy
ROA 186.91% Strong Buy
Operating Margin NaN%
Debt / Equity 2423.24% Strong Buy
P/E 92.90 Strong Buy
P/B 4,279.74 Strong Buy

Income Statement

Quarter data
Year 2018 2017
Earnings Per Share Diluted 0.100.11
Net Profit Margin --
Weighted Average Shares Outstanding --
Revenue --
Weighted Average Shares Outstanding (Diluted) --
Gross Profit --
Dividend per Share --
Operating Income --
Gross Margin --
Income Tax Expense --
EBIT Margin --
Net Income --
Cost of Revenue --
Earnings Before Tax Margin --
EBIT --
EBITDA --
Profit Margin --
Operating Expenses --
Earnings Per Share Basic 0.100.11
Earnings before Tax --
Interest Expense -0.01-0.01

Balance Sheet Statement

Quarter data
Year 2018 2017 2016
Short-term debt ---
Other Assets ---
Total current liabilities 0.080.160.84
Cash and cash equivalents 0.689.201.49
Long-term debt ---
Cash and short-term investments 0.689.201.49
Total debt ---
Inventories ---
Deferred revenue ---
Goodwill and Intangible Assets ---
Total non-current liabilities ---
Total non-current assets -0.052.11
Total liabilities 1.259.574.56
Total assets 0.799.524.00
Other comprehensive income ---
Short-term investments ---
Property, Plant & Equipment Net -0.052.11
Net Debt -0.68-9.20-1.49
Investments ---
Total shareholders equity ---
Retained earnings (deficit) ---
Long-term investments ---
Receivables 0.120.280.40
Payables 0.080.160.84
Total current assets 0.799.471.89

Cash Flow Statement

Quarter data
Year 2018 2017
Investing Cash Flow -0.05-2.09
Free Cash Flow --0.02
Depreciation & Amortization --
Net cash flow / Change in cash -0.01-7.71
Effect of forex changes on cash --
Financing Cash Flow 13.181.54
Dividend payments --
Stock-based compensation --
Investment purchases --
Acquisitions and disposals --
Capital Expenditure -0.02
Operating Cash Flow --

Retained Earning Schedule

Year 2016 2017 2018
Retained Earnings (Previous Year) ---
Net Income ---
Stock Dividends ---
Dividend Paid ---
Retained Earnings ---

PPE Schedule

Year 2016 2017 2018
Gross PPE --0
Annual Depreciation -02
Capital Expenditure --0
Net PPE -02

Intangible and Goodwill Schedule

Year 2016 2017 2018
Intangible and Goodwill (Previous Year) ---
New Purchases ---
Intangible and Goodwill ---

About


Elran Haber
Healthcare
Biotechnology
NASDAQ Capital Market

Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. The Company is engaged in creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.